This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Allscripts (MDRX) Up 4.5% Since Q4 Earnings: What's Driving It?
by Zacks Equity Research
Allscripts' (MDRX) stock rallies on better-than-expected fourth-quarter performance and recent alliances.
Merit Medical's (MMSI) Product Included in FDA's Program
by Zacks Equity Research
Receipt of the Breakthrough Device Designation for Merit Medical's (MMSI) Embosphere Microspheres is expected to improve patient outcome.
AmerisourceBergen (ABC) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about AmerisourceBergen's (ABC) strength in its World Courier business.
4 Stocks in Spotlight With AI Making Inroads in MedTech
by Riya Anand
MedTech stocks like Medtronic (MDT), Stryker (SYK), Allscripts Healthcare Solutions (MDRX) and Syneos Health (SYNH) are evolving rapidly in the field of AI-driven technologies.
Dexcom's (DXCM) CGM Gets FDA's Breakthrough Device Designation
by Zacks Equity Research
Dexcom's (DXCM) CGM's use in the hospital setting is likely to be more effective in glycemic management and improved patient outcomes.
Henry Schein (HSIC) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Henry Schein's (HSIC) favorable dental business trends.
Veeva (VEEV) Beats on Q4 Earnings, Narrows '23 Revenue View
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q4 results reflect impressive performances by both of its segments.
Masimo's (MASI) SedLine Receives FDA's Pediatric Indication
by Zacks Equity Research
The latest FDA clearance for Masimo's (MASI) SedLine is likely to improve brain function monitoring in pediatric patients.
Inogen (INGN) Stock Surges 16.5% Despite Q4 Earnings Miss
by Zacks Equity Research
Inogen's (INGN) fourth-quarter results benefit from higher revenues across the majority of its geographical segments.
OPKO Health's (OPK) Q4 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
OPKO Health's (OPK) fourth-quarter results benefit from continued strength in its Pharmaceuticals segment.
Merit Medical's (MMSI) Q4 Earnings, Revenues Top Estimates
by Zacks Equity Research
Merit Medical (MMSI), in the fourth quarter, benefits from revenue growth in both its segments, and from majority of the product categories within its Cardiovascular unit.
Allscripts' (MDRX) Q4 Earnings Beat Estimates, Margins Up
by Debanjana Dey
Allscripts' (MDRX) robust Q4 results demonstrate strength in both segments.
AllScripts Healthcare (MDRX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
AllScripts (MDRX) delivered earnings and revenue surprises of 154.84% and 0.08%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic deals.
DENTSPLY SIRONA (XRAY) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) fourth-quarter results are likely to reflect strong segmental performance.
Fulgent Genetics (FLGT) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
In terms of COVID-19 NGS revenues, Fulgent Genetics (FLGT) is expected to have witnessed a rise in testing volume on increased demand through the Q4 months.
NextGen (NXGN)-Verato Tie Up to Improve Patient Insights
by Zacks Equity Research
NextGen (NXGN) expects to deliver better insights into patient health history with its latest collaboration with Verato.
Medtronic (MDT) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Medtronic (MDT) might report low procedure volumes in the fiscal third quarter in markets where its technologies are used in more deferrable procedures.
Zacks Industry Outlook Highlights: Change Healthcare, Allscripts Healthcare Solutions and Computer Programs and Systems, Inc
by Zacks Equity Research
Change Healthcare, Allscripts Healthcare Solutions and Computer Programs and Systems, Inc. are highlighted in this Industry Outlook article.
AllScripts Healthcare (MDRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
AllScripts (MDRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Veeva Systems (VEEV) Vault CDMS to Aid Idorsia's Clinical Trials
by Zacks Equity Research
Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Veeva Development Cloud business.
3 Medical Info Systems Stocks Braving Industry-wide Headwinds
by Urmimala Biswas
Medical Info Systems stocks like Change Healthcare (CHNG), Allscripts Healthcare Solutions (MDRX) and Computer Programs and Systems, Inc. (CPSI) are expected to gain despite pandemic-led disruptions.
AMN Healthcare (AMN) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
AMN Healthcare's (AMN) fourth-quarter results are likely to reflect solid demand in some of the areas of its business.
Is iRadimed (IRMD) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how iRadimed (IRMD) and AllScripts Healthcare (MDRX) have performed compared to their sector so far this year.
Quidel (QDEL) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Quidel's (QDEL) fourth-quarter results are likely to reflect continued strength across its SARS-related products.